TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,059,316 | -39.0% | 565,919 | +4.7% | 0.00% | -50.0% |
| Q2 2023 | $8,299,822 | -26.5% | 540,353 | +7.6% | 0.00% | -33.3% |
| Q1 2023 | $11,297,402 | +16.0% | 502,330 | +8.5% | 0.00% | 0.0% |
| Q4 2022 | $9,739,224 | -14.6% | 463,111 | +0.1% | 0.00% | -25.0% |
| Q3 2022 | $11,405,000 | +0.1% | 462,842 | -1.6% | 0.00% | 0.0% |
| Q2 2022 | $11,392,000 | -6.3% | 470,147 | -0.4% | 0.00% | 0.0% |
| Q1 2022 | $12,161,000 | -14.5% | 471,880 | +3.0% | 0.00% | 0.0% |
| Q4 2021 | $14,227,000 | +26.5% | 458,320 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $11,250,000 | +20.4% | 463,879 | -27.5% | 0.00% | +33.3% |
| Q2 2021 | $9,340,000 | -44.6% | 640,115 | -5.3% | 0.00% | -50.0% |
| Q1 2021 | $16,871,000 | +10.9% | 675,650 | +21.0% | 0.01% | 0.0% |
| Q4 2020 | $15,217,000 | – | 558,310 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |